17
Apr
€75 million EIB Group quasi-equity investment to support Africa’s first end-to-end multi-vaccine manufacturing facility in South Africa enables an additional $20 million and further mobilization in senior financing from the IFC.
This investment is backed by a European Commission EFSD+ guarantee under the Human Development Accelerator (HDX), part of the EU's Global Gateway strategy.
Project to produce key vaccines for cholera, polio, meningitis and pneumonia, strengthening the prevention of serious infectious diseases in children.
More than 340 skilled and...